SUBMITTED NEWS RELEASE
A radiation oncologist with experience in clinical trials will bring those skills to cancer patients at Renown Health. Daniel Weed, MD, recently joined the Renown Institute for Cancer in February 2011. Patients of Dr. Weed will have improved access to top-level medical experts.
“I enjoy being in an atmosphere with challenging cases and the technology to meet them,” Dr. Weed said on his decision to leave Indiana and move to Reno.
Dr. Weed will explore patient access in clinical trials, including potentially more than 200 as they become available through the partnership between Renown Health and the University of California, San Francisco Medical Center.
Dr. Weed said he will tailor patient care to each patient’s needs, using the technology that would best suit their recovery. This includes state-of-the-art equipment such as Varian and TomoTherapy, as well as high-dose-rate Brachytherapy radiation treatments.
Dr. Weed has been board certified in Radiation Oncology since 2005. He is a graduate of the Indiana University School of Medicine in Indianapolis and Wittenberg University in Springfield, Ohio. Among his previous work is as Medical Director of Radiation Oncology at Methodist Hospital and Clarian West Hospital, where he worked on publishing intra-operative experience and co-chaired the Hoosier Oncology Group head and neck trials.
He also has several published articles on cancer care, including a recent co-authored article on breast cancer treatment preferences and pending co-authored articles on intra-operative radiation therapy for head and neck cancer.
Dr. Weed joins a cancer program that is the only one in northern Nevada to be recognized with three national cancer accreditations: the National Accreditation Program for Breast Centers, a program administered by the American College of Surgeons; the region’s first and only Radiation Oncology Accreditation for cancer radiation treatments; and the region’s first Comprehensive Cancer Program Accreditation, which the institute has held for more than 23 years.